Matinas BioPharma Holdings Management
Management criteria checks 3/4
Matinas BioPharma Holdings' CEO is Jerry Jabbour, appointed in Mar 2016, has a tenure of 8.67 years. total yearly compensation is $1.60M, comprised of 37.4% salary and 62.6% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $5.53K. The average tenure of the management team and the board of directors is 6.1 years and 6.8 years respectively.
Key information
Jerry Jabbour
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 37.4% |
| CEO tenure | 8.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 6.1yrs |
| Board average tenure | 6.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$21m |
| Jun 30 2024 | n/a | n/a | -US$23m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$2m | US$598k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$21m |
| Mar 31 2023 | n/a | n/a | -US$21m |
| Dec 31 2022 | US$2m | US$575k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$4m | US$545k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Jun 30 2021 | n/a | n/a | -US$22m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$3m | US$500k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$19m |
| Dec 31 2019 | US$1m | US$445k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$15m |
| Mar 31 2019 | n/a | n/a | -US$15m |
| Dec 31 2018 | US$1m | US$366k | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$15m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$1m | US$299k | -US$33m |
Compensation vs Market: Jerry's total compensation ($USD1.60M) is above average for companies of similar size in the US market ($USD647.72K).
Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.
CEO
Jerry Jabbour (50 yo)
8.7yrs
Tenure
US$1,599,551
Compensation
Mr. Jerome D. Jabbour, also known as Jerry, J. D., Co-founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.7yrs | US$1.60m | 0.18% $ 5.5k | |
| Chief Financial Officer | 5.8yrs | US$626.60k | 0.038% $ 1.1k | |
| Executive Director and Head of Manufacturing & Supply Chain | 6.1yrs | no data | no data |
6.1yrs
Average Tenure
Experienced Management: MTNB's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.7yrs | US$1.60m | 0.18% $ 5.5k | |
| Independent Director | 11.3yrs | US$141.50k | 1.87% $ 56.4k | |
| Independent Director | 11yrs | US$155.00k | 0.26% $ 7.8k | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Independent Director | 4.2yrs | US$145.50k | no data | |
| Independent Director | 6.8yrs | US$136.00k | 0.12% $ 3.5k | |
| Independent Chairman of the Board | 7.6yrs | US$159.00k | 0.057% $ 1.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3yrs | US$140.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data |
6.8yrs
Average Tenure
63yo
Average Age
Experienced Board: MTNB's board of directors are considered experienced (6.8 years average tenure).